Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Abstract Background Breast cancer is the second most common cancer worldwide, the most common among women, and the most frequent cause of death among women in less developed regions. Trastuzumab is a humanized monoclonal antibody that downregulates the extracellular domain of the HER2 protein. Using...

Full description

Bibliographic Details
Main Authors: Noga Gershon, Yakir Berchenko, Peter S. Hall, Daniel A. Goldstein
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-effectiveness
Trastuzumab
Sub-Saharan Africa
Online Access:http://link.springer.com/article/10.1186/s12962-019-0174-7

Internet

http://link.springer.com/article/10.1186/s12962-019-0174-7

Similar Items